John Beynon, Ph.D
John holds a doctorate in chemistry from U.C. Davis. His graduate coursework emphasized analytic instrumentation and methods. His thesis focused on utilizing X-ray crystallography to study the structure and function of proteins, such as microbial enzymes and plant photoreceptors. Before attending graduate school Dr. Beynon worked at Sandoz Pharmaceuticals in their Quality Assurance group.
Away from the office, John enjoys paddle boarding, running, and enjoying the outdoors.
- University of California – Hastings College of the Law, J.D.
- University of California – Davis, Ph.D., Chemistry
- The Colorado College, B.A., Chemistry
- U.S. District Court, Northern District of California
- U.S. District Court, Central District of California
- U.S. District Court, Southern District of California
- U.S. District Court, Eastern District of California
- U.S. Patent & Trademark Office
Intellectual Ventures v. Hynix & Elpida. Represented Intellectual Ventures in a patent infringement suit asserting Intellectual Ventures’ memory patent portfolio against DRAM and NAND Flash memory products. Hynix ultimately settled on favorable terms to Intellectual Ventures.
AMKOR v. Tessera. Represented AMKOR in arbitration regarding its royalty obligations under a license agreement to semiconductor packaging technology.
Applera v. Bio-Rad & Stratagene. Represented Applera in a patent litigation asserting Applera’s groundbreaking “Real-Time PCR” patent portfolio. Both defendants settled on terms favorable to Applera.
Samsung v. Kodak. Represented Samsung as a complainant and a respondent in two separate ITC actions adverse to Kodak. Technology involved digital photography and hand-held electronic devices.
PDL BioPharma v. Alexion. Represented PDL BioPharma in patent litigation asserting PDL’s portfolio of patents on humanized antibodies. The case settled after a claim construction on terms favorable to PDL.
Sorensen v. Lexar Media. Defended Lexar in patent infringement allegations against its NAND Flash thumb drive products. The case settled on terms favorable to Lexar.